No Data
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $3 to $8
Optimistic Outlook for Fate Therapeutics' FT819 in Cell-Therapy Space Amid Promising Phase 1 Results
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties
Wedbush Remains a Hold on Fate Therapeutics (FATE)
Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties
MilaDing : What to collect.